» Articles » PMID: 40056177

ZEB1 Transcription Factor Induces Tumor Cell PD-L1 Expression in Melanoma

Abstract

Tumor cells can evade antitumor immune response by expressing the PD-L1 ligand, leading to the inhibition of PD-1-expressing T lymphocytes. The mechanisms that regulate PD-L1 expression in cancer cells are imperfectly characterized. The transcription factor ZEB1, a major regulator of phenotype switching in melanoma cells, was shown to promote immune escape in melanoma by repressing T cell infiltration. Using inducible models of phenotype switching and ZEB1 gain/loss-of-function melanoma, we show that ZEB1 binds to the CD274 (PD-L1) promoter, directly enhancing PD-L1 mRNA transcription and its expression at the cell membrane. Furthermore, using single-cell spatial analyses on human primary melanoma samples, we demonstrate the correlation of ZEB1 and PD-L1 expression in tumor cells. Overall, these data identify ZEB1-mediated regulation of PD-L1 tumor expression as a mechanism that could contribute to immune escape in melanoma.

References
1.
Xu J, Yang X, Pan J, Fan H, Mei J, Hua D . Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer. J Oncol. 2022; 2022:3224373. PMC: 8888121. DOI: 10.1155/2022/3224373. View

2.
Caramel J, Papadogeorgakis E, Hill L, Browne G, Richard G, Wierinckx A . A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24(4):466-80. DOI: 10.1016/j.ccr.2013.08.018. View

3.
Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

4.
Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View

5.
Mak M, Tong P, Diao L, Cardnell R, Gibbons D, William W . A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2015; 22(3):609-20. PMC: 4737991. DOI: 10.1158/1078-0432.CCR-15-0876. View